マイダテック・ファ―マ（MTP）Midatech Pharma PLC - 米国株銘柄紹介 | 米国株を知る場所 nasdaqchart（ナスダックチャート）

MTPのチャート

MTPの企業情報

symbol	MTP
会社名	Midatech Pharma PLC （マイダテック・ファ―マ）
分野（sector）	Health Care ヘルスケア
産業（industry）	Major Pharmaceuticals
業種	バイオテクノロジ―_メディカルリサ―チ医療関連（Health Care）
概要	事業概要 Midatech Pharma PLC is an early-stage biopharmaceutical company that focuses on commercializing and developing products in oncology and other therapeutic areas. The Company''s segments include Pipeline Research and Development and Commercial. The Pipeline Research and Development segment seeks to develop products using the nanomedicine and sustained release technology platforms. The Commercial segment distributes and sells the commercial products. Its products include Zuplenz Gelclair Oravig and Soltamox. Zuplenz is an oral soluble film indicated for moderately emetogenic chemotherapy-induced nausea and vomiting (CINV) radiotherapy-induced nausea and vomiting (RINV) and post-operative nausea and vomiting (PONV). Gelclair is a product indicated for the management and relief of pain due to oral mucositis. Oravig is an orally dissolving buccal tablet approved for oral thrush. Soltamox is an oral liquid solution of tamoxifen citrate for the prevention of breast cancer. マイダテック・ファ―マはイギリスの医療系持株会社。子会社を通じ、ナノ化薬物の持続放出技術を用いた治療薬の開発と商業化に従事。主に糖尿病、肝臓がん、卵巣がん、悪性脳腫瘍、及び神経系や眼系の病気に対する治療において、適切なタイミングで、適切な患部に薬物を送達したり、既存薬の持続放出を可能にさせる。本社はアビングドン。
本社所在地	65 Innovation Drive Milton Park Abingdon Oxfordshire OX14 4RQ GBR
代表者氏名	―
代表者役職名	―
電話番号	―
設立年月日	41883
市場名	NASDAQ Small Cap
ipoyear	―年
従業員数	85人
url	www.midatechpharma.com
nasdaq_url	https://www.nasdaq.com/symbol/mtp
adr_tso	2920413
EBITDA	EBITDA ー
終値（lastsale）	0.58
時価総額（marketcap）	1693839.54
時価総額	時価総額 ―
売上高	売上高 --
企業価値(EV)	企業価値(EV) ー
当期純利益	当期純利益 --
決算概要	決算概要 --

MTPのテクニカル分析

MTPのニュース

Why Is Midatech Pharma (BDRX) Stock Up 64% Today? 2023/03/28 12:34:55 InvestorPlace

Midatech Pharma (BDRX) stock is rocketing higher on Tuesday after the pharmaceutical company announced a new research program.

Midatech Pharma - £5m fund-raise to provide headroom to end-FY23 2023/02/13 11:34:00 Finanz Nachrichten

Midatech announced on 9 February a private placement to certain US institutional investors to raise US$6m (£5m) in gross proceeds. The issue will comprise 10.3m ADS units (or ADS-equivalent pre-fun…

Midatech gets non-compliance notice from Nasdaq 2023/02/03 11:17:26 Seeking Alpha

Midatech Pharma (MTP) received a notice from Nasdaq for not being in compliance with the $1 minimum bid price requirement rule for continued listing on the exchnage.The…

Bioasis Technologies Inc. Announces Termination of Arrangement Agreement with Midatech Pharma plc 2023/01/23 14:22:00 GlobeNewswire

NEW HAVEN, Conn., Jan. 23, 2023 (GLOBE NEWSWIRE) -- BIOASIS TECHNOLOGIES INC . (OTCQB:BIOAF; TSX.V:BTI) (the “ Company ” or “ Bioasis ”), a multi-asset rare and orphan disease biopharmaceutical company developing clinical stage programs based on epidermal growth factor and a differentiated, proprietary xB 3 ™ platform for delivering therapeutics across the blood-brain barrier (“ BBB ”) and the treatment of central nervous system (“ CNS ”) disorders in areas of high unmet medical need, today announced that it has terminated the arrangement agreement (the “ Arrangement Agreement ”) dated December 13, 2022, as amended December 18, 2022, between Bioasis and Midatech Pharma plc (“ Midatech ”). The Arrangement Agreement provided for Midatech’s acquisition of all of Bioasis’ issued and outstanding shares in exchange for ordinary shares of Midatech by way of a statutory plan of arrangement under the laws of British Columbia (the “ Arrangement ”).

Midatech Pharma Shares Rise on Revised Placement Terms, Intention to Remain on AIM 2022/12/19 09:24:00 MarketWatch

By Anthony O. Goriainoff Shares in Midatech Pharma PLC rose Monday after the company said it had agreed to revise the terms of a private placement, and that…